

Interlocutory Orders, Etc.

IN THE MATTER OF

GRIFOLS, S.A.

AND

**TALECRIS BIOTHERAPEUTICS HOLDINGS
CORP.**

Docket No. C-4322. Order, September 5, 2017

Letter Order approving the Application filed by Grifols, S.A. to modify the Contract Manufacturing Agreement.

LETTER ORDER APPROVING MODIFICATION

John R. Ingrassia, Esq.
Proskauer Rose LLP
Counsel for Grifols, S.A.

*Re: In the Matter of Grifols, S.A., and Talecris Biotherapeutics
Holdings Corp. Docket No. C-4322*

Dear Mr. Ingrassia:

Pursuant to Rule 2.41(f) of the Commission Rules of Practice, the Commission has determined to approve the Application filed by Grifols, S.A., on June 12, 2017, to modify the Contract Manufacturing Agreement (“CMA”) incorporated into the Decision and Order in this matter by approving the draft Amendment to the CMA. In according its approval to Grifol’s Application, the Commission has relied upon the information submitted by Grifols S.A., and the Commission has assumed that information to be accurate and complete.

By direction of the Commission.

Interlocutory Orders, Etc.

IN THE MATTER OF

**CHINA NATIONAL CHEMICAL
CORPORATION,
ADAMA AGRICULTURAL SOLUTIONS LTD.,
AND
MAKHTESHIM AGAN OF NORTH AMERICA,
INC. D/B/A ADAMA**

Docket No. C-4610. Order, September 26, 2017

Letter notifying China National Chemical Corporation of the Commission's decision to waive prior approval and public comment regarding modifications to the formulation services agreement.

LETTER WAIVING PRIOR APPROVAL AND COMMENT FOR
MODIFICATIONS TO AN AGREEMENT

Peter Guryan, Esq.
Simpson Thacher & Bartlett LLP

Re: In the Matter of China National Chemical Corporation, et al., Docket No. C-4610

Dear Mr. Guryan:

This is in reference to an application for approval of a modification filed by China National Chemical Corporation ("ChemChina") and received on September 14, 2017 ("Application"). Pursuant to the Decision and Order in Docket No. C-4610, ChemChina requests Commission approval of its proposal to modify the formulation services agreement between Makhteshim Agan of North America, Inc. (a subsidiary of ChemChina) and Amvac Chemical Corporation.

After consideration of ChemChina's Application and pursuant to the authority delegated to me under Rule 2.41(t)(5)(ii) of the Commission's Rules of Practice, 16 C.F.R. § 2.41(t)(5)(ii), I hereby waive the requirements for Commission approval and the public comment period for the modifications to the formulation services agreement described in ChemChina's Application.